I thank the senators for their contribution to this debate. As I understand it, there is broad support in the chamber for this bill and I thank senators for that. Let me take this opportunity, in response, to try to answer some of the questions that have been raised. My understanding is that Senator Heffernan and Senator Xenophon have raised the case involving Sanofi-Aventis, where the High Court invalidated a patent. As I understand this particular case, or the suggestion has been made—